MA53636A - Agent de traitement de troubles dermatologiques - Google Patents
Agent de traitement de troubles dermatologiquesInfo
- Publication number
- MA53636A MA53636A MA053636A MA53636A MA53636A MA 53636 A MA53636 A MA 53636A MA 053636 A MA053636 A MA 053636A MA 53636 A MA53636 A MA 53636A MA 53636 A MA53636 A MA 53636A
- Authority
- MA
- Morocco
- Prior art keywords
- agent
- treatment
- dermatological disorders
- dermatological
- disorders
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/48—Nerve growth factor [NGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- Immunology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Psychology (AREA)
- Neurology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18194930 | 2018-09-17 | ||
| EP18203665 | 2018-10-31 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA53636A true MA53636A (fr) | 2021-12-22 |
Family
ID=67989007
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA053636A MA53636A (fr) | 2018-09-17 | 2019-09-17 | Agent de traitement de troubles dermatologiques |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20220064243A1 (fr) |
| EP (1) | EP3852785A1 (fr) |
| JP (1) | JP2022502359A (fr) |
| KR (1) | KR20210061388A (fr) |
| CN (1) | CN113226350A (fr) |
| AU (1) | AU2019343514A1 (fr) |
| BR (1) | BR112021003820A2 (fr) |
| CA (1) | CA3111158A1 (fr) |
| MA (1) | MA53636A (fr) |
| MX (1) | MX2021002983A (fr) |
| WO (1) | WO2020058217A1 (fr) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2021318524A1 (en) * | 2020-07-27 | 2023-02-02 | Human Cell Co. | NGF variants, production, compositions, and therapeutic uses |
| CA3207296A1 (fr) * | 2021-01-06 | 2022-07-14 | The Penn State Research Foundation | Methodes et materiaux de traitement contre la perte de cheveux |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE59810555D1 (de) | 1998-10-09 | 2004-02-12 | Scil Proteins Gmbh | Verfahren zur Gewinnung von aktivem Beta-NGF |
| WO2003075949A1 (fr) | 2002-03-12 | 2003-09-18 | Bio-Click Technologies Ltd. | Methode et composition de traitement de lesions cutanees avec un facteur de croissance epidermique |
| ITRM20060367A1 (it) * | 2006-07-13 | 2008-01-14 | Lay Line Genomics Spa | Muteine del hngf usi terapeutici e composizioni farmaceutiche |
| WO2010128519A1 (fr) | 2009-05-04 | 2010-11-11 | Kumar C Jairaj | Procédé de détection d'une neuropathie et de prédiction de l'apparition d'un ulcère du pied chez des êtres humains atteints de pahtologies telles que le diabète sucré |
| SI2672984T1 (sl) | 2011-12-19 | 2015-11-30 | Wacker Chemie Ag | Novi proNGF mutanti in njihove uporabe pri izdelavi beta-NGF |
| US20180086805A1 (en) | 2016-05-20 | 2018-03-29 | Chiesi Farmaceutici S.P.A. | proNGF mutants and uses thereof for the preparation of NGF mutants |
-
2019
- 2019-09-17 MX MX2021002983A patent/MX2021002983A/es unknown
- 2019-09-17 AU AU2019343514A patent/AU2019343514A1/en active Pending
- 2019-09-17 EP EP19769794.9A patent/EP3852785A1/fr active Pending
- 2019-09-17 KR KR1020217011307A patent/KR20210061388A/ko active Search and Examination
- 2019-09-17 WO PCT/EP2019/074767 patent/WO2020058217A1/fr unknown
- 2019-09-17 JP JP2021514556A patent/JP2022502359A/ja active Pending
- 2019-09-17 MA MA053636A patent/MA53636A/fr unknown
- 2019-09-17 BR BR112021003820-5A patent/BR112021003820A2/pt unknown
- 2019-09-17 US US17/277,240 patent/US20220064243A1/en active Pending
- 2019-09-17 CA CA3111158A patent/CA3111158A1/fr active Pending
- 2019-09-17 CN CN201980060757.0A patent/CN113226350A/zh active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2019343514A1 (en) | 2021-04-15 |
| CA3111158A1 (fr) | 2020-03-26 |
| CN113226350A (zh) | 2021-08-06 |
| EP3852785A1 (fr) | 2021-07-28 |
| WO2020058217A1 (fr) | 2020-03-26 |
| BR112021003820A2 (pt) | 2021-05-25 |
| MX2021002983A (es) | 2021-05-14 |
| JP2022502359A (ja) | 2022-01-11 |
| US20220064243A1 (en) | 2022-03-03 |
| KR20210061388A (ko) | 2021-05-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA45481A (fr) | Utilisation d'exosomes pour le traitement de maladies | |
| MA51200A (fr) | Nouveaux composés et compositions pharmaceutiques associées pour le traitement de maladies | |
| MA51673A (fr) | Composés destinés au traitement de troubles dépendant de la kinase | |
| MA44875A (fr) | Compositions pour le traitement de troubles acido-basiques | |
| FR3046933B1 (fr) | Inhibiteurs nlrp3 pour le traitement des pathologies cutanees inflammatoires | |
| MA47719A (fr) | Esketamine pour le traitement de la dépression | |
| MA51139A (fr) | Dérivés de 1-(pipéridinocarbonylméthyl)-2-oxopipérazine pour le traitement du cancer | |
| IL279260A (en) | KDM1A inhibitors for the treatment of diseases | |
| MA47207A (fr) | Composés utiles pour le traitement de troubles du tractus digestif | |
| MA49141A (fr) | Composés pyrrolopyridine-aniline destinés au traitement d'affections de la peau | |
| MA42953A (fr) | Composés et compositions pour le traitement de troubles oculaires | |
| FR3032353B1 (fr) | Composition pharmaceutique et dispositif pour le traitement de la douleur | |
| MA51672A (fr) | Composés destinés au traitement des troubles kinases-dépendants | |
| MA51738A (fr) | Composés pour le traitement de la douleur | |
| MA54077A (fr) | Polythérapie pour le traitement de maladies hématologiques | |
| MA43800A (fr) | Octréotide par voie orale pour le traitement de maladies | |
| MA53741A (fr) | Procédés de traitement de troubles myéloprolifératifs | |
| MA39927A (fr) | Inhibiteurs de glyt1 pour le traitement de troubles hématologiques | |
| MA50391A (fr) | Nouveaux composés et compositions pharmaceutiques associées pour le traitement de troubles inflammatoires | |
| MA52761A (fr) | Schéma posologique destiné au traitement de troubles liés à la pi3k | |
| MA47212A (fr) | Méthodes de traitement de troubles neurologiques | |
| MA53568A (fr) | Médicaments pour le traitement de maladies ophtalmiques | |
| MA43825A (fr) | Schémas posologiques pour le traitement d'infections fongiques | |
| MA53636A (fr) | Agent de traitement de troubles dermatologiques | |
| MA49140A (fr) | Composés hétéroaromatiques-aniline fusionnés pour le traitement de troubles dermiques |